Evidence map›Paper›PMID 39409897›Full record

ReviewCancers2024

Stereotactic Body Radiotherapy (SBRT) for the Treatment of Primary Localized Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Agata Suleja, Mateusz Bilski, Ekaterina Laukhtina, Tamás Fazekas, Akihiro Matsukawa, Ichiro Tsuboi, Stefano Mancon, Robert Schulz, Timo F W Soeterik, Mikołaj Przydacz and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Agata SulejaIII Department of Radiotherapy and Chemotherapy, Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO), 44-102 Gliwice, Poland.
Mateusz BilskiDepartment of Radiotherapy, Medical University of Lublin, 20-059 Lublin, Poland.ORCID 0000-0002-4962-3028
Ekaterina LaukhtinaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-8953-0272
Tamás FazekasDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-0068-4089
Akihiro MatsukawaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Ichiro TsuboiDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Stefano ManconDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Robert SchulzDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Timo F W SoeterikDepartment of Radiation Oncology, University Medical Center, 3584 Utrecht, The Netherlands.
Mikołaj PrzydaczDepartment of Urology, Jagiellonian University Medical College, 30-688 Krakow, Poland.ORCID 0000-0002-7381-7420
Łukasz NykSecond Department of Urology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland.ORCID 0000-0001-6502-1484
Paweł RajwaDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Wojciech MajewskiRadiotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO), 44-102 Gliwice, Poland.
Riccardo CampiDepartment of Experimental and Clinical Medicine, University of Florence, 50139 Florence, Italy.ORCID 0000-0001-5237-0888
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Marcin MiszczykDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-4375-0827

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextSurgery is the gold standard for the local treatment of primary renal cell carcinoma (RCC), but alternatives are emerging. We conducted a systematic review and meta-analysis to assess the results of prospective studies using definitive stereotactic body radiotherapy (SBRT) to treat primary localised RCC. EVIDENCE ACQUISITION: This review was prospectively registered in PROSPERO (CRD42023447274). We searched PubMed, Embase, Scopus, and Google Scholar for reports of prospective studies published since 2003, describing the outcomes of SBRT for localised RCC. Meta-analyses were performed for local control (LC), overall survival (OS), and rates of adverse events (AEs) using generalised linear mixed models (GLMMs). Outcomes were presented as rates with corresponding 95% confidence intervals (95% CIs). Risk-of-bias was assessed using the ROBINS-I tool. EVIDENCE SYNTHESIS: Of the 2983 records, 13 prospective studies (

conclusionsThe short-term results suggest that SBRT is a valuable treatment method for selected inoperable patients (or those who refuse surgery) with localised RCC associated with low rates of high-grade AEs and excellent LC. However, until the long-term data from randomised controlled trials are available, surgical management remains a standard of care in operable patients.

Indexed as

clear cell carcinomaCyberKnifedefinitive treatmentkidney cancernon-metastaticradiation

Identifiers

PMID39409897
PMCPMC11475739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.